Enliven Therapeutics (ELVN) closed at $44.25 on October 30, 2026, down 1.8% from the previous close, on volume of 807,511 shares (30-day average 1,613,283).
Data as of October 30, 2026.
30-Oct-2026
PRNewswire (Wed, 14-Oct 4:30 PM ET)
ELVN Gains a Clear FDA Path for a 450-Patient Phase 3 Relcobatinib Study in Previously Treated CML
Market Chameleon (Wed, 7-Oct 7:04 AM ET)
PRNewswire (Tue, 6-Oct 4:06 PM ET)
Enliven Therapeutics to Present at Upcoming Investor Conferences
PRNewswire (Thu, 3-Sep 4:05 PM ET)
PRNewswire (Mon, 31-Aug 6:06 PM ET)
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update
PRNewswire (Wed, 5-Aug 4:05 PM ET)
Enliven Therapeutics Raises $400 Million Through Upsized Public Offering: What Investors Should Know
Market Chameleon (Fri, 12-Jun 6:41 AM ET)
Market Chameleon (Fri, 9-Jan 6:14 AM ET)
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Enliven Therapeutics trades on the NASDAQ stock market under the symbol ELVN.
As of October 30, 2026, ELVN stock price declined to $44.25 with 807,511 million shares trading.
ELVN has a beta of 1.30, meaning it tends to be more sensitive to market movements. ELVN has a correlation of 0.03 to the broad based SPY ETF.
ELVN has a market cap of $3.16 billion. This is considered a Mid Cap stock.
In the last 3 years, ELVN traded as high as $62.32 and as low as $9.80.
The top ETF exchange traded funds that ELVN belongs to (by Net Assets): VTI, IWM, VXF, IWO, IBB.
ELVN has outperformed the market in the last year with a price return of +84.6% while the SPY ETF gained +12.3%. However, in the short term, ELVN had mixed performance relative to the market. It has underperformed in the last 3 months, returning -18.0% vs +2.1% return in SPY. But in the last 2 weeks, ELVN shares have fared better than the market returning +18.6% compared to SPY -1.0%.
ELVN support price is $43.59 and resistance is $46.57 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ELVN shares will trade within this expected range on the day.
